A systematic review and meta-analysis of the efficacy of lixisenatide in the treatment of patients with type 2 diabetes
Author:
Affiliation:
1. HEALTH - Institute for Biomedicine and Health Sciences; Joanneum Research; Graz Austria
2. Evidence Based Medicine Review Center, Department of Internal Medicine; Medical University of Graz; Graz Austria
Funder
Sanofi
Publisher
Wiley
Subject
Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1111/dom.12269/fullpdf
Reference68 articles.
1. https://www.iqwig.de/download/V09-04_Abschlussbericht_Leitlinienrecherche_und-bewertung_fuer_das_DMP_Diabetes_mellitus_Typ_2.pdf
2. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD);Inzucchi;Diabetologia,2012
3. http://www.idf.org/sites/default/files/postmeal%20glucose%20guidelines.pdf
4. Primary care physicians and insulin initiation: multiple barriers, lack of knowledge or both?;Jabbour;Int J Clin Pract,2008
5. Mechanisms of action of glucagon-like peptide 1 in the pancreas;Doyle;Pharmacol Ther,2007
Cited by 26 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. The Use of Glucagon-like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus Does Not Increase the Risk of Pancreatic Cancer: A U.S.-Based Cohort Study;Cancers;2024-04-23
2. GLP-1RA Essentials in Gastroenterology: Side Effect Management, Precautions for Endoscopy and Applications for Gastrointestinal Disease Treatment;Gastroenterology Insights;2024-02-18
3. Weight loss and side-effects of liraglutide and lixisenatide in obesity and type 2 diabetes mellitus;Primary Care Diabetes;2023-10
4. Contemporary Classification of Glucagon-Like Peptide 1 Receptor Agonists (GLP1RAs);Diabetes Therapy;2021-07-15
5. Protective properties of GLP‐1 and associated peptide hormones in neurodegenerative disorders;British Journal of Pharmacology;2021-05-29
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3